Copyright AFP 2017-2022. All legal rights reserved.
As Thailand relaxed cannabis guidelines in June 2022, Fb posts circulated with a assert that having “one particular to two drops of cannabis everyday can cure 39 disorders”, which include Alzheimer’s, diabetes and superior blood strain. Nonetheless, the posts are misleading there is no proof that cannabis or its derivatives can overcome these illnesses, but they can be made use of to relieve sure circumstances, according to well being industry experts. They told AFP the use of hashish for medical purposes must be monitored by a healthcare provider.
“Be informed before applying #ganja to appear after your wellness,” reads a Thai-language Fb post from June 11, 2022, shared around a hundred occasions.
An accompanying infographic is made up of photos of dropper bottles and Thai-language text that translates to English as: “39 awful health conditions can be cured, just consider 1-2 drops before mattress every single day. Is effective as equally therapy and defense.”
The write-up names sicknesses which includes Alzheimer’s, diabetic issues, cancer, schizophrenia, depression, paralysis, psoriasis, HIV and much more.
Hashish extracts protect a broad range of items that normally include high concentrations of cannabinoids, chemical substances found in the hashish plant. These can be marketed in good or liquid type, which can then be put less than the tongue utilizing a spray or dropper.
The psychoactive tetrahydrocannabinol (THC) is the ideal recognized cannabinoid, while cannabidiol (CBD) does not generate a “large” but has been shown to be productive for a array of ailments these as stress or sleeplessness.
Screenshot of the deceptive Facebook article, taken on June 14, 2022.
The posts circulated as Thailand — where persons caught with cannabis earlier faced up to 10 many years in prison and a hefty wonderful — comfortable its rules on June 9 2022, making it possible for permitted users to possess and grow the plant underneath new tips.
Cannabis has been made use of as a traditional herb for generations in Thailand but was banned many years in the past.
Although CBD has been accredited for clinical use, hashish extracts with a lot more than .2 {fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} concentration of THC keep on being unlawful.
The infographic has also been shared with a equivalent assert on Facebook here, below, here and right here.
However, health and fitness gurus advised AFP the declare is misleading.
‘Insufficient evidence‘
Affiliate professor of preventive medication at Thailand’s Chulalongkorn College Dr Thira Woratanarat — who would only remark on the legalised CBD — claimed most of the diseases and ailments described in the declare have not been verified treatable with the substance.
Thira explained it is a established option treatment for clients undergoing chemotherapy, sufferers with cerebral palsy, long-term pain and to relieve seizures.
“It is not a substitute but can be applied as an choice in scenario the primary medication is unavailable,” mentioned Thira, who also mentioned that it has been verified protected and effective within a constrained scope.
Nevertheless, other disorders — these kinds of as Alzheimer’s, diabetic issues, despair and HIV that are pointed out in the misleading posts — have not been clinically established to be treatable with CBD.
He urged clients seeking to acquire CBD for its purported health advantages to seek healthcare information.
Not for direct cancer treatment
Dr Nicha Zungsontiporn, a lecturer from the oncology division of Chulalongkorn College and The King Chulalongkorn Memorial Medical center, also instructed AFP on June 20, 2022, that extracts from cannabis are not able to be applied to handle cancer right.
Nicha stated: “CBD is used to help clients taking most cancers treatment or chemotherapy.
“It is not utilised as a immediate treatment for cancer sufferers, but is made use of to mitigate the facet-consequences of the cure approach,” she extra, which could include things like nausea and lack of urge for food.
Meanwhile, Thira warned that each day use of CBD could lead to material dependency.
“Continued use will end result in our body’s amplified tolerance, which can direct to a want for larger dosage.”
A person thing is genuine of the worldwide cannabis business. Just when you imagine that the gentle at the stop of the tunnel is invariably just a further teach (i.e., at minimum a delay if not a setback) there are glimmers of hope on the horizon. This is unquestionably real of the British CBD current market of late.
Below is the newest zinger. According to polling from an field group, the Association for the Cannabinoid Field (ACI), one fifth of British grownups have experimented with CBD flower or oil and 58{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of respondents overall believe it has well being rewards.
Outside of this, the other details elicited from study respondents was enlightening, if not a more indicator that the British CBD biz is moving into a total new entire world. This starts with the actuality (although unsurprising, offered present market place dynamics) that a whopping 38{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of these surveyed also noted getting their goods on the net.
On the other hand, this is far from the only appealing progress of late in the UK—and the two this and a handful of other developments are in part the strategic work of the ACI.
Beyond this fascinating marketplace snapshot, the team has been actively bringing together senior associates of the political class and recently commissioned a report contacting for the authorities to consider a far more energetic management in reform to make certain the British sector develops into a person that is world class.
Why the U.K. Cannabis Market Is So Appealing
On the other side of the Brexit divide, the British theoretically have much more regulatory flexibility to pursue new avenues of cannabis reform a great deal far more swiftly than their neighbors across the Channel. There are various ways this is true—and even greater, prospective for rapid reform exists on each the medical and leisure aspect. This has been blazingly evident in just the previous weeks as a British Parliamentary team recommended the entire scrapping of Novel Food stuff regulation (at the exact time their European counterparts more delayed 19 pending applications).
On the genuine products entrance, past the conversation about getting rid of the will need for just one distinct and intricate regulation, this has been an appealing spring. The U.K., on your own in Europe, has begun to formalize its CBD market—and even further in a way unseen throughout the area (except maybe in Switzerland proper now, also exterior of the E.U.).
Here is a person of the biggies. It is achievable to now promote CBD products in a way unseen in Germany, for example. This is since the German Narcotic Law still covers CBD. This can make it quite complicated to put stakes in the ground (whilst the landscape is obviously shifting albeit on authorized grounds as treacherous as quicksand). The total discussion about on the net product sales is also continuing in a way nevertheless enveloped in a imprecise and as a end result often harmful authorized path in other countries.
Throughout the water from France, on the other hand, and it is crystal clear that at the very least in some elements of the biz, the Brits are sallying forth in phrases of blazing new trails to reform. This is of study course correct even while a lot of and substantial complications nevertheless abound.
How CBD Marketplaces Go the Reform Dialogue Ahead
There has been an ongoing strategic discussion afoot in the U.K. ever considering the fact that 2018 on how very best to shift the all round subject of full and last reform forward. Some have prompt that a “CBD strategy” was a person way to do that—namely jettison everything out of the political push for fast alter with a THC percentage greater than .03{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} (if not zero in the extract and food items discussion). This, in combination with health care buyers who could be counted on to foyer for the two CBD and THC legalization, was observed as the very best way to go the needle.
It is however unclear if that will be legitimate. The British clinical market has languished, in section for the reason that of the concentrate on an exclusive, privately insured phase of the seriously ill. There are, in immediate comparison, thousands of legal German people (even even though of system the procedure listed here is much from perfect or even near to what it really should be).
Beyond this, there are also raising phone calls from many influential segments of the country, ranging not just from police chiefs who now dare to buck the status quo, to the mayor of London, and of program, individual and marketplace associations who are nicely heeled and politically connected.
What is crystal clear, no issue which section finishes up pushing the needle eventually into entire reform, is that hashish legalization in all its quite a few faceted glories is afoot in the U.K. in a new way. And regardless of the a lot of icebergs however dead forward, is effectively on its way to mainstream acceptance by the majority of the population, who also will have entry to it 1 way or a different.
Technically legal federally, state legality depends on the state
Not legal federally, state legality varies by state
Detected on Drug Test
Cannabidiol is not detected, but if the preparation has any THC in it, that could be detected.
Yes
Hemp vs. Marijuana
Hemp and marijuana are technically the same kind of plant—cannabis. However, hemp plants have no more than 0.3{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} (by dry weight) of THC. Marijuana has 5{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}–20{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} THC. Hemp cannot get you high.
Psychoactive
According to the World Health Organization (WHO), a psychoactive substance is a substance that, when consumed, impacts mental processes (thinking, mood, perception, consciousness). This definition doesn’t necessarily only refer to recreational drugs—it can also include substances like nicotine or caffeine.
Synthetic vs. Natural
Synthetic CBD is made in a lab with chemical or biological ingredients. Natural CBD is taken from cannabis plants.
Chemical Differences
Both CBD and THC are cannabinoids from the plant Cannabis sativa. They both have the same chemical makeup: 21 carbon atoms, 30 hydrogen atoms, and two oxygen atoms. However, the arrangement of the atoms differs. The body reacts to them as two different substances.
Effects of CBD vs. THC
The effects of CBD and THC on the body are quite different. Knowing the difference between the two can help you know what to expect if you use these substances.
Medicinal
CBD can have many different medicinal effects, and has multiple mechanisms of action—at least 20 have been identified thus far. It has been found to:
Mediate antiepileptic effects: It binds to a protein called GPR55 that triggers seizures.
Mediate pain signaling and inflammation: It acts on receptors in these pathways.
Relieve neuropathic pain and have an antidepressant effect: It acts like selective serotonin receptor inhibitors (SSRIs), which are medications used to treat depression.
Decrease psychotic symptoms: This effect may be seen in people with schizophrenia (a mental health condition in which there is an altered perception of reality). It may have an additive effect when used with traditional antipsychotic drugs (when used together, there may be better control of hallucinations and delusions).
Reduce anxiety symptoms
More studies are needed to evaluate CBD’s mechanisms of action and whether its effects are clinically significant consistently.
Drugs with cannabinoids (CBD and/or THC) can be helpful in treating nausea and vomiting in people undergoing cancer chemotherapy, and weight loss and loss of appetite associated with human immunodeficiency virus (HIV) and AIDS. They may also help with chronic pain and symptoms of multiple sclerosis.
Recreational
CBD is not used as a recreational drug like marijuana is. While it can help you feel more relaxed or less anxious, it doesn’t make you “high.”
Recreationally, effects of THC can include:
Alteration of the senses
Alteration of your sense of time
Mood changes
Trouble with body movement
Impaired memory
Trouble thinking or problem-solving
Hallucinations or delusions
Psychosis (losing touch with reality): Risk is highest when regularly using high-potency marijuana.
Industrial and Cosmetic Uses of CBD
CBD can offer relief for various conditions, including skin and cosmetic disorders such as eczema (an inflammatory skin condition) and psoriasis (an autoimmune skin condition).
The human endocannabinoid system (ECS) helps with bodily homeostasis (maintaining a steady state). It helps to maintain skin homeostasis, and when it is dysregulated (out of balance), hyper/hypopigmentation (skin patches with increased or decreased color), atopic dermatitis, hair growth or loss, itch, and acne can occur.
Because CBD has anti-inflammatory properties, it can help with disorders that cause inflammation and/or itching, like atopic dermatitis. More research needs to be done, but CBD may also help with acne because it may inhibit bacterial growth and the production of more oil-making skin cells.
Although CBD shows promise for cosmetic uses for the skin and hair, more studies need to be done to evaluate its effectiveness.
What’s Legal?
Although CBD is not a psychoactive substance, it isn’t legal in every state. In order for CBD to be legal in your state, it needs to be legal at both the federal and state levels.
While the Farm Bill legalized the production of any part of the cannabis plant with a THC concentration of 0.3{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} or lower, states have the final say.
CBD Legal States
Even though CBD cannot get you “high,” it is not legal in every state. While some states have no restrictions on CBD, others have legalized CBD only for medical purposes. Some regulate it depending on whether it was derived from hemp or marijuana. Others have not legalized it at all.
Laws continuously change. Before you purchase or use any CBD product, even without THC, it’s best to check your state laws. One resource to do so is the National Conference of State Legislatures, on their State Medical Cannabis Laws page.
THC Legal States
Laws regarding THC are actively changing. It is important to check the most current laws in each state. Some state laws vary in the level of THC that is legal, or for what purpose THC can be consumed.
Drug tests specifically look for THC and its breakdown products. CBD should not produce a positive test.
While CBD shouldn’t show up on a drug test, some CBD products do have THC, so it may cause a positive THC result on a drug test. Many CBD products are not regulated, so you don’t know what exactly is in them or how much THC they contain.
The bottom line is that if CBD or THC is illegal in your state or is forbidden in your workplace, it’s best to not use them or limit your usage.
Side Effects
As with any ingested substance, there are potential side effects to both CBD and THC. Additional side effects of CBD than the ones already listed can include:
Changes in alertness, usually drowsiness
Gastrointestinal issues like diarrhea or lack of appetite
Mood changes like irritability or agitation
Side effects of THC (in addition to the recreational ones) may include:
Changes in blood pressure and heart rate
Red eyes
Increased risk of mood disorders
Lung irritation with chronic usage
Types of CBD and THC
There are different types of CBD and THC. Knowing the differences can help you make a choice about which is best for you.
The types of CBD include:
Whole plant CBD:Uses all of the hemp compounds but is usually too thick for general use
Full spectrum CBD: Contains none of the waxes or oils from whole plant CBD, but has traces of THC
Broad spectrum CBD: Contains no THC but has other cannabinoids, terpenes, and flavonoids
Pure CBD (isolate): Contains only CBD, no THC, and no other compounds
The types of THC include:
THC-a: This is the most common type of THC in cannabis, and is the precursor to the other kinds. It does not produce psychoactive effects.
Delta 9 THC: This is responsible for producing the typical psychoactive effects of marijuana, and also helps relieve bodily tension and increases appetite.
Delta 8 THC: This makes up less than 1{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of the cannabis plant and is supposed to be half as psychoactive as delta 9.
THCP (tetrahydrocannabiphorol): This is said to have approximately 33{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} more potency and strength than delta 9 but medicinal benefits are unknown.
THCV (tetrahydrocannabivarin):This is not as effective in binding to receptors. In large doses it can be psychoactive, but not in low doses.
Summary
While CBD and THC are from the same plant, the cannabis plant, they are very different. Both can increase relaxation and sleepiness, improve mood, and relieve pain, but CBD does not have the same psychoactive properties that THC does.
There are different kinds of CBD. It’s good to know what kind you are using because some may have traces of THC in them. Knowing more about CBD and THC can help you make informed decisions about what you choose to consume.
A Word From Verywell
While CBD and THC may be legal in some states, in other states there are restrictions on both. Before ordering or using these substances, it’s always a good idea to check the laws in your state about both CBD and THC.
Frequently Asked Questions
Which type of THC/CBD offers instant pain relief?
Smoking a product containing THC (like a marijuana “joint”) or vaping CBD oil can start relieving pain in a few minutes. Creams and edibles can take a bit longer, even up to a few hours for edibles, since they have to go through the digestive tract.
Are the effects of delta-8 THC similar to CBD?
The effects of delta-8 THC are more potent than CBD. Whereas CBD does not get you high, delta-8 does. It is similar to delta-9, which produces the high and side effects of marijuana than it is to CBD.
Can THC/CBD make anxiety worse?
Everyone’s experience with THC or CBD is different. While THC in low doses tends to reduce anxiety, THC has been shown to increase anxiety in high doses. CBD has been found to decrease anxiety at multiple doses.
Should you tell your healthcare provider you use CBD or THC?
It’s good to let your healthcare provider know if you use CBD or THC. They can interact with certain medications and may cause physical health issues, so your healthcare provider should know if you use these substances.
Hashish can at times be used as a system of persistent soreness relief, but there is a ton about cannabis’ well being gains and related dangers that scientists even now don’t comprehend.
New research located that some hashish merchandise made up of THC and CBD factors might support with the small-phrase advancement of persistent soreness.
The conclusions also advise a danger of sedation and dizziness involved with use, and there desires to be additional information on the very long-term influence.
Lots of persons encounter long-term discomfort or pain that lasts for an prolonged period of time. Professionals are continually looking into new methods of suffering reduction and new medicine alternatives. One spot of fascination is the use of cannabis items as a strategy of suffering reduction.
A current systematic evaluation published in the Annals of Interior Drugs located that hashish products and solutions could possibly help take care of chronic agony in the short phrase. Even so, professional medical pros need to have to weigh this against the potential disadvantages of enhanced dizziness and sedation. It is also unclear whether or not these merchandise are valuable in the extended time period.
Persistent suffering lasts for months or extended, and tens of millions of adults in the U.S. working experience serious pain. For the reason that quite a few men and women practical experience long-term ache, gurus are constantly operating to assess prospective treatments and therapies. As experts continue to study the medicinal employs of cannabis, one particular space of fascination is how doctors could use it to treat chronic suffering.
Cannabis is a plant, and individuals can use distinctive plant portions to produce several merchandise. The two major compounds of cannabis are cannabidiol (CBD) and tetrahydrocannabinol (THC).
Some goods have both of those THC and CBD. The CBD part does not result in brain-altering results, whilst the THC portion causes the high persons to expertise when they use cannabis. Some of these related merchandise are obtainable in the U.S., although some are not. Presently, the Meals and Drug Administration has approved utilizing two medicines that comprise THC: Marinol and Syndros.
This systematic overview sought “To assess the gains and harms of cannabinoids for continual pain.” The phrase Cannabinoids refers to compounds that incorporate equally THC and CBD.
Researchers utilized quite a few databases to accumulate the experiments they reviewed. They integrated studies published in English that resolved the use of hashish products and solutions as a procedure for persistent soreness. Especially, the examine involved a abide by-up or treatment time of 4 months or far more. The examination integrated placebo-controlled randomized controlled trials and cohort scientific studies in which the use of cannabis had a concurrent regulate team.
They incorporated a whole of 25 experiments in their investigation. Researchers examined the merchandise used in the scientific studies and looked at the THC-to-CBD ratio. Did the products comprise a significant THC amount of money and a low CBD amount, was the total about equivalent or did the solution have a low THC amount and a significant CBD quantity?
The benefits of the review had been rather missing. The data was inadequate for some products and solutions to ascertain if they successfully handled continual soreness. Nonetheless, researchers did discover some results that supported the efficiency of hashish goods:
Synthetic oral products and solutions with a superior THC-to-CBD ratio could lead to short-term chronic suffering relief.
Sublingual extracted cannabis products with nearly equal THC-to-CBD proportions could possibly be connected with short-term enhancements in chronic ache.
Nonetheless, they located that individuals who use these items may possibly also encounter an increased hazard for dizziness and sedation, which physicians will will need to weigh towards the likely positive aspects. Total, they also discovered that authorities require to conduct much more experiments about the very long-time period outcomes of cannabis use.
Study author Marian S. McDonagh located the absence of info stunning. She described:
“With so substantially excitement all around hashish-associated items, and the uncomplicated availability of leisure and medical marijuana in several states, buyers and sufferers may well think there would be more proof about the benefits and side results. Regrettably, there is really little scientifically valid analysis into most these items.”
Professor Winston Morgan, pharmacology and toxicology specialist with the University of East London, not associated with the research, mentioned the next to Healthcare Information Right now:
“For any new mediation it need to improve on recent treatments in phrases of each efficacy and basic safety. For decades cannabinoids have promised but never ever really deliver. This evaluation which requires an attention-grabbing solution on the advantages and harms of cannabinoids for continual agony, advise that only average added benefits can be attained with merchandise with higher THC ratios, but these are far more probable to result in adverse effects. Regrettably these adverse outcomes may well also restrict extended phrase use.”
This systematic critique yielded some beneficial information. Even so, it also experienced quite a few limitations. Initial of all, researchers built particular selections throughout the review process that may perhaps have impacted the evaluate benefits, these kinds of as how sure cannabis merchandise ended up classified. The procedures of examining the details do have a danger of imprecision.
They have been also unable to assess publication bias on quite a few results owing to out there information and did not contain studies that weren’t prepared in English. Last but not least, different reports utilized distinctive interventions, and some scientific tests lacked particulars. For some merchandise, there was basically insufficient proof.
Scientists of the systematic overview approach to update the overview quarterly so that they can insert new proof as it emerges. In general, this paper demonstrates some of the recent understandings of cannabis and the need to have for even further analysis. Physicians can take a look at evaluations like this a single to assist guideline their clients in the remedy of chronic agony.
“This new dwelling proof assessment is just the sort of resource clinicians need to explain for people the locations of likely guarantee, the cannabis formulations that have been analyzed and, importantly, the major gaps in know-how.”
CBD of Denver (OTCMKTS: CBDD) has been under accumulation in recent weeks and recently broke north of its trading range. The stock had fallen to lows of $0.0016 from highs near $0.04 in early 2021, and the cannabis market looks ripe for a rally as there are 8 states with Marijuana legalization measures on the ballet including Texas, Oklahoma, South Dekota, Ohio, North Dekota, Nebraska, Missouri, Maryland, Iowa, and Arkansas.
CBDD hit the OTC in November 2018 and Microcapdaily reported on it at the time, stating in our article from November 16 “CBDD is a publicly traded company listed on OTC Markets and traded under the stock symbol CBDD. The Company is currently developing innovative CBD products and related social networking. CBDD is the new ticker for VGMI. The Company is led by new CEO Nicholas Sprung, a serial entrepreneur who used to be CEO of a Ski Company with an ambitious vision to make CBD of Denver a leader in the booming CBD space. The Company has established its principal corporate office located at 4610 South Ulster Street, Suite 150, Denver, CO 80237, where it has rented office space.
CBD of Denver (OTCMKTS: CBDD) is a Distributor of CBD and Cannabis flower and a producer of a full line of CBD oil and unique products sold in Switzerland and throughout Europe. CBD of Denver, Inc. is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis. Through our Rockflowr brands we have built a very strong European customer base by focusing on top quality products and meaningful customer relationships.
Earlier this year CBDD reported it filed audited financial statements for fiscal year 2021 on April 15, 2022 reporting a record $23.5 million in revenue and net income of $0.33 million. Management credits a fast growing market for its success and first profitable year. According to CBD of Denver CEO Paul Gurney: “While our internal momentum continues to grow, the market itself is providing increasing tailwinds. Just this week, Swiss authorities greenlighted a recreational usage pilot in the city of Basel to begin over the summer. As this trend potentially spreads across Switzerland, and ultimately across Europe, CBD of Denver is ideally positioned to capitalize on the rapidly evolving opportunities,” added Gurney. “I want to thank our shareholders for their continued support. I firmly believe we are on a great trajectory and look forward to reporting on our ongoing successes.”
While fiscal year 2021 financial results were exceptional the Company was negatively impacted in Q1, 2022, due to the reintroduction of COVID controls across Europe and pricing pressure on CBD flower. These trends have already reversed, and the Company’s April revenue nearly surpassed the entire first quarter’s revenue as prices began to stabilize. CBD of Denver generated $908,086 revenue in the first three months of 2022, with a net loss of $314,248 mainly on an inventory write down of $102,856. CEO Paul Gurney said “On the surface, the numbers don’t tell the full story and should be viewed in context. While revenues at 3.5{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} margins don’t usually result in overall profitability, my mandate is to transform this business from a commodity trader into a higher-margin, multi-pronged, health and wellness powerhouse in Europe and Asia.”
To Find out the inside Scoop on CBDD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
The Company recently acquired 100{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} of Mellow, a CBD ecommerce distribution platform and technology company, with capabilities in the UK, Europe, and Asia, for an undisclosed sum. The acquisition is expected to close in the second quarter of 2022. With operations in Asia, Mellow gives CBDD an entrance into the rapidly evolving CBD markets in the fast-growing Asia Pacific region. The Mellow technology stack will accelerate the Company’s plans to become the go-to name for cannabis across all parts of the value chain in international markets. his acquisition will combine technology and retail e-commerce distribution alongside manufacturing and supply chain infrastructure to create a turnkey solution for the CBD industry across Europe. According to CBDD management “Mellow is also the leading multi-channel distribution partner of choice for globally minded CBD and Hemp brands in Asia too, with our own physical store network and ecommerce channels. This is a global play.”
The Company recently expanded into the German medical cannabis market with the hiring of Bijan Hezarkhani to lead CBD of Denver’s growth in this fast growing European market. Bijan has extensive experience in the cannabis industry, including building out a medical cannabis franchise in Germany. He was the business development manager for Khiron Life Sciences for the last three years, visiting doctors and pharmacies in Germany to build Khiron’s medical cannabis business. Previously, he spent time at Canopy Growth as a business analyst covering Europe. Bijan will be the head of the Company’s medical cannabis sales in Germany and will be based in Frankfurt.
Germany officially approved medical cannabis in 2017. Germany is the largest medical cannabis market in Europe at 15 tonnes annually and generated approximately US$300 million of revenue in 2021. According to Forbes Magazine, over a million patients in Germany will have access to medical cannabis by 2024, with the German medical market worth €7.7 billion by 2028. The German market appears to be moving closer to adult-use legalization, a market estimated at 400 tonnes annually, making it critical to have the infrastructure in place in country. With 83 million people, Germany is the most attractive market in Europe for cannabis.
On May 26 CBDD announced mellow has signed an agreement with UK luxury CBD consumer brand OTO to act as their distribution partner in Asia. OTO, headquartered in London, is a premium positioned consumer CBD wellness brand, specializing in offering sophisticated products at the luxury end of the industry price spectrum. Mellow aims to provide the OTO brand experience through its mellow Asia division, which is operated out of the Hong Kong market, and which already operates a network of physical retail stores under the mellow banner as well as an eCommerce site
CBDD CEO said Paul Gurney said: “We are extremely excited to welcome the OTO brand to the mellow portfolio of brands in Hong Kong. This agreement will combine retail and technology/e-commerce distribution to enable mellow to continue the great work that the OTO team have achieved in other markets, and in doing so, will position OTO as the leading luxury CBD and wellness brand in the Asian markets. There is no other company present in the industry in Hong Kong with offering close to that of OTO. We are very pleased to be able to make this announcement, and we have much more in store ahead.”
Microcapdaily reported on CBDD in November 2020 in the $0.002 level right before the stock skyrocketed to over $0.03 per share in December. We stated in our article “CBD of Denver Inc. (OTCPINK: CBDD) is making an explosive move up the charts after the Company announced record revenues of $5,963,820.00 with gross profits of $484,666.00 for the 3rd quarter ended September 30, 2020. CBDD is an emerging player in the booming global CBD oil and CBD consumer health market which is expected to reach USD $123.2 billion by 2027, expanding at a CAGR of 25.6{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} over the forecast period. It’s easy to see why penny stock speculators are so bullish on CBDD; the Company’s subsidiary Rockflowr GmbH is quickly emerging as one of the leading wholesale companies for CBD in Switzerland. Rockflowr sources its hemp flower from the United States in large quantities and its distribution has grown to more than 7 countries in Europe. Rockflowr GmbH generated the bulk of CBDD revenues.”
Currently trading at a $31 million market valuation CBD of Denver has come a long way since we first reported on it in 2018, when the Company as nothing more than an ambitious vision. CBDD had a stellar year in 2021 reporting a record $23.5 million in revenue and net income of $0.33 million. While fiscal year 2021 financial results were exceptional the Company was negatively impacted in Q1, 2022, due to the reintroduction of COVID controls across Europe and pricing pressure on CBD flower. These trends have already reversed, and the Company’s April revenue nearly surpassed the entire first quarter’s revenue as prices began to stabilize. CBDD has been under accumulation in recent weeks and recently broke north of its trading range. The stock had fallen to lows of $0.0016 from highs near $0.04 in early 2021, and the cannabis market looks ripe for a rally as there are 8 states with Marijuana legalization measures on the ballet including Texas, Oklahoma, South Dekota, Ohio, North Dekota, Nebraska, Missouri, Maryland, Iowa, and Arkansas. Microcapdaily gave the heads up on CBDD in November 2020 when the stock was $0.002 right before it ran to over $0.03 in December 2020.We will be updating on CBDD when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBDD.
Disclosure: we hold no position in CBDD either long or short and we have not been compensated for this article.
Cannabinoid science touches on an astoundingly wide range of subject areas. With cannabinoids – endogenous, plant-derived, and synthetic – and their receptors positioned at the hub, investigation in the area spins out in all directions like the spokes on a bicycle wheel.
But in contrast to with a completely “true” wheel, some of these spokes bear additional pounds than many others. They may well have a more powerful proof foundation, as in cannabinoids’ link with inflammatory procedures. Many others have been issue to higher notice about the many years from patients and activists outside academia, like the “legacy” medical cannabis ailments of glaucoma, nausea, and insomnia.
The latest scientific scientific tests validate longstanding statements of therapeutic efficacy for each of these problems that assisted start healthcare marijuana into the mainstream, but much more is left to study. Listed here are some new papers on these important spokes of the wheel.
Glaucoma
Glaucoma presents a convenient rhyme in Peter Tosh’s 1978 strike “Bush Doctor” (So legalize marijuana / Down in this article in Jamaica / It’s the only cure for glaucoma) and a cheap punchline at professional medical marijuana’s expenditure in numerous more recent films and Television set displays. But it is also a severe situation impacting some 70 million persons that can induce irreversible loss of vision.
Mostly many thanks to the endeavours and 1976 court victory of Washington, D.C. activist Robert Randall, cannabis has extensive been identified to present short-expression aid by decreasing intraocular stress. In actuality, glaucoma was the first sign for which the U.S. authorities furnished health care hashish to a handful of sufferers (like Randall) commencing in the late 1970s.
But nearly 50 percent a century afterwards, cannabis’ exact molecular system of action is unsure, and the growth of cannabinoid-dependent glaucoma medicines remains a obstacle. In a March 2022 paper in the journal Planta Medica1, researchers with Germany’s TU Dortmund College evaluate latest results, with an eye toward new pharmaceuticals. Amid other factors, they deal with the relative capacity of various cannabinoids to reduce intraocular pressure (THC and CBN complete improved than CBD, which in 1 experiment essentially increased tension in mice) and the distribution of CB1 and CB2 receptors, TRPV channels, and other cannabinoid targets all over the human eye (they’re just about everywhere).
The authors also existing a listing of remaining study desires: far more medical research in people, because most to date have been in mice, pigs, or rabbits a higher comprehending of the position of the increased endocannabinoid system in the pathophysiology of the eye and, just as importantly, the improvement of formulations for eye-drop supply of cannabinoids, which are improperly soluble in water.
Nausea
One more of professional medical cannabis’ most prevalent and longstanding indications is nausea. The plant has been utilised to handle nausea for millennia, and its means to offset the severe aspect results of chemotherapy for most cancers and AIDS was pivotal to the emergence and accomplishment of the clinical cannabis motion in the 1990s. But even below more work is needed, researchers with the University of New Mexico argue in their April 2022 paper in the Journal of Medical Gastroenterology.2 Couple research have calculated serious-time effects of typical and commercially available cannabis-dependent merchandise, they compose.
Their answer? To analyze a lot more than three years’ really worth of info submitted to a smartphone application identified as Releaf that assists users monitor and optimize their cannabis consumption. Among June 2016 and July 2019, 886 people today applied the application to check a full of 2,220 self-administered, inhaled cannabis-use classes supposed to take care of nausea. These records involve baseline and progressive nausea scores, enabling the researchers to retrospectively assess symptom change around time – and, additional to the place, to seem for associations amongst level or diploma of advancement and product or pressure variety.
Extra than 96 per cent of users professional symptom aid in a person hour, and often in just 5 minutes. “Among product or service properties, flower and concentrates yielded the strongest, yet similar results,” the authors compose. “Products labeled as Cannabis indica underperformed these labeled as Cannabis sativa or hybrid, and joints ended up connected with higher symptom aid than pipes or vaporizers.”
In periods using flower, better THC and lower CBD content have been typically linked with higher symptom aid. This is a 2nd reminder that even outside of its pronounced psychological effects, for some physiological results THC appears to have more therapeutic price than its large-profile cousin.
Slumber
Insomnia has historically been an additional major driver of healthcare hashish use. In a recent study of somewhere around 27,000 grown ups in the United States and Canada, much more than a quarter reported making use of cannabis for medical causes amid these, 46 p.c cited troubles sleeping as a motive for use – slightly fewer than for the prime two answers, agony (53 percent) and nervousness (52 {fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}3). (Bear in mind these in situation Spouse and children Feud at any time asks what the “survey says” about why people use pot.)
But does it certainly enable? “Burgeoning evidence implies a role of the endocannabinoid technique in regulating the circadian sleep-wake cycle” … but “robustly developed scientific tests verifying efficacy in snooze-disordered populations are limited,” write the Australia-primarily based authors of a new overview posting in the journal Upper body4. Whilst some scientific tests have proven that cannabinoids are in truth beneficial in sleeplessness condition and sleep apnea, most scientific studies to date are minimal by modest sample measurements, deficiency of rigorously controlled study models, and large threat of bias, they insert.
The bottom line? “While current curiosity in, and uptake of, medicinal cannabis use for sleep disorders could have surpassed the proof-foundation, there is a solid rationale for continued investigation into the therapeutic potential of cannabinoids.” And so the wheel keeps on turning.
Nate Seltenrich, an independent science journalist primarily based in the San Francisco Bay Area, addresses a extensive vary of subjects together with environmental wellness, neuroscience, and pharmacology.
Copyright, Job CBD. Could not be reprinted devoid of permission.
Screenshot of the deceptive Facebook article, taken on June 14, 2022.
/GettyImages-1181145058-6b8df581a9914ed1a272254c66b646de.jpg "A Chart to Help You Understand Cannabis")
